ZimVie Inc.
Description
ZimVie Inc., together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to support dental tooth replacement and restoration procedures worldwide. It operates through The Dental Segment. The company offers dental implant systems; biomaterials; prosthetic and abutment products, surgical instrumentation, and kits; and patient-specific restorative solutions, such as abutments, bars, implant bridges, and hybrid restorations under the BellaTek brand name. It provides bone grafts, barrier membranes, and collagen wound care products; virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and intra-oral scanners; and Implant Concierge, a web-based treatment planning and surgery guide service. The company sells its products to oral surgeons, dental specialists, general dentists, dental laboratories, and other dental organizations, including DSOs, as well as educational, medical, and governmental entities, hospitals, and surgery centers through direct sales representatives, agents, and distributors. ZimVie Inc. was incorporated in 2021 and is headquartered in Palm Beach Gardens, Florida with additional facilities around the globe.
About
CEO
Mr. Vafa Jamali
Employees
2,600
Instrument type
Common Stock
Sector
Healthcare
Industry
Medical Devices
MIC code
XNGS
Address
4555 Riverside Drive, Palm Beach Gardens, FL 33410, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 1, 2023 | -0.02 | 0.08 | 0.10 | -500.00% |
| Aug 2, 2023 | 0.03 | 0.17 | 0.14 | 466.67% |
| May 4, 2023 | 0.06 | 0.25 | 0.19 | 316.67% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 1 | — | 2 |
| Average estimate | — | 0.14 | — | 0.74 |
| Low estimate | — | 0.14 | — | 0.66 |
| High estimate | — | 0.14 | — | 0.82 |
| Last year EPS | — | 0.08 | — | 0.59 |
[stock_revenue_estimate]
Growth estimates
Current qtr
24.050%
Next qtr. (Mar 2025)
175.630%
Current year
-15.680%
Next year (Dec 2025)
27.910%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 457.43M | 463.29M | 472.31M | 912.43M | 1.06B |
| Cost of revenue | 167.05M | 169.35M | 175.97M | 312.91M | 333.90M |
| Gross profit | 290.38M | 293.95M | 296.34M | 599.52M | 721.60M |
| Operating expense | |||||
| Research & development | 26.16M | 31.15M | 27.29M | 49.25M | 55.60M |
| Selling general and admin | 248.96M | 253.16M | 207.58M | 533.54M | 605.40M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -11.26M | -17.34M | 33.18M | -68.76M | -22.80M |
| Non operating interest income | |||||
| Income | — | — | — | — | — |
| Expense | 20.23M | 10.87M | 405,000 | 302,000 | 100,000 |
| Other income expense | -19.36M | -26.29M | -12.19M | -152.29M | -4.80M |
| Pretax income | -50.85M | -54.50M | 20.58M | -221.35M | -27.70M |
| Tax provision | 5.20M | -7.60M | 4.19M | -42.35M | 200,000 |
| Net income | -393.28M | -63.88M | -95.25M | -179.00M | -27.90M |
| Basic EPS | -14.87 | -2.45 | -3.65 | -6.86 | -1.07 |
| Diluted EPS | -14.87 | -2.45 | -3.65 | -6.86 | -1.07 |
| Basic average shares | 26.45M | 26.10M | 26.10M | 26.10M | 26.10M |
| Diluted average shares | 26.45M | 26.10M | 26.10M | 26.10M | 26.10M |
| EBITDA | 110.76M | 108.31M | 162.07M | 67.14M | 112.50M |
| Net income from continuing op. | -393.28M | -63.88M | -95.25M | -179.00M | -27.90M |
| Minority interests | — | — | — | -89,000 | -100,000 |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 1.21B | 1.64B | 1.83B | 1.95B | 2.11B |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 71.51M | 68.28M | 100.40M | 27.40M | 37.00M |
| Other short term investments | — | — | — | — | — |
| Accounts receivable | 65.17M | 67.03M | 164.24M | 193.70M | 188.90M |
| Other receivables | — | — | — | — | — |
| Inventory | 79.60M | 77.43M | 246.83M | 283.00M | 270.70M |
| Prepaid assets | 13.33M | 22.63M | 25.40M | 21.90M | 20.90M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | 242.77M | 293.64M | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 852,000 | 1.23M | 25.38M | 21.90M | 20.90M |
| Non current assets | |||||
| Properties | — | 270.04M | 315.14M | 324.30M | 324.40M |
| Land and improvements | 6.70M | 6.69M | 7.25M | 7.20M | 7.20M |
| Machinery furniture equipment | 19.63M | 19.39M | 41.88M | 30.10M | 29.30M |
| Construction in progress | 8.18M | 14.00M | 7.73M | 3.50M | 3.80M |
| Leases | — | — | — | — | — |
| Accumulated depreciation | -126.62M | -122.86M | -418.19M | -406.00M | -381.30M |
| Goodwill | 638.58M | 658.68M | 1.30B | 1.44B | 1.72B |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 114.35M | 138.69M | 766.18M | 891.00M | 917.40M |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 291.84M | 647.01M | 75.66M | 75.10M | 73.10M |
| Total liabilities | 795.85M | 883.45M | 375.36M | 458.70M | 442.30M |
| Current liabilities | |||||
| Accounts payable | 27.79M | 26.50M | 45.03M | 49.70M | 50.30M |
| Accrued expenses | 23.17M | 34.75M | 40.99M | 40.50M | 38.20M |
| Short term debt | 4.05M | 3.42M | 12.63M | 31.60M | 12.80M |
| Deferred revenue | — | — | — | — | — |
| Tax payable | 2.86M | 13.77M | 6.28M | 6.60M | 5.80M |
| Pensions | — | — | — | — | — |
| Other current liabilities | 115.74M | 136.24M | 79.67M | 97.80M | 90.70M |
| Non current liabilities | |||||
| Long term debt | 517.88M | 542.19M | 45.32M | 57.60M | 73.20M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | 265,000 | 2.15M | 129.48M | 155.20M | 159.10M |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 9.06M | 8.93M | 15.98M | 19.70M | 12.20M |
| Shareholders equity | |||||
| Common stock | 271,000 | 262,000 | 1.49B | 1.49B | 1.71B |
| Retained earnings | -440.81M | -47.53M | — | — | — |
| Other shareholders equity | -72.96M | -91.15M | -42.78M | 4.50M | -40.30M |
| Total shareholders equity | 409.49M | 758.60M | 1.45B | 1.49B | 1.67B |
| Additional paid in capital | 923.00M | 897.03M | — | — | — |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | 900,000 |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | -393.28M | -63.88M | -95.25M | -179.00M | -27.90M | -459.40M |
| Depreciation | 121.69M | 122.79M | 129.72M | 134.33M | 135.10M | 147.70M |
| Deferred Taxes | -17.09M | -70.42M | -22.09M | -22.81M | -18.60M | -28.00M |
| Stock-Based Compensation | 27.02M | 30.29M | 7.31M | 5.95M | 7.10M | 5.60M |
| Other Non-Cash Items | 3.25M | 1.17M | — | — | — | — |
| Accounts Receivable | 29.57M | -34.64M | 27.17M | -1.07M | 9.80M | 32.90M |
| Accounts Payable | -24.76M | 21.84M | -6.59M | -3.03M | -500,000 | 700,000 |
| Other Assets & Liabilities | 6.14M | 20.90M | 24.69M | 9.61M | 14.20M | 50.80M |
| Operating Cash Flow | -247.47M | 28.05M | 64.96M | -56.02M | 119.20M | -249.70M |
| Investing Activities | ||||||
| Capital Expenditures | -12.49M | -26.55M | -56.65M | -38.27M | -53.00M | -48.30M |
| Net Intangibles | — | — | — | — | — | — |
| Net Acquisitions | — | — | — | -8.42M | -27.60M | — |
| Purchase of Investments | — | — | — | — | — | — |
| Sale of Investments | — | — | — | — | — | — |
| Investing Cash Flow | -15.17M | -28.66M | -60.35M | -49.51M | -84.60M | -50.30M |
| Financing Activities | ||||||
| Long-Term Debt Issuance | 4.76M | 595.00M | — | — | — | 1.10M |
| Long-Term Debt Payments | -29.30M | -58.54M | -16.91M | -668,000 | — | -39.70M |
| Other Financing Charges | -3.40M | 1.75M | 89.25M | -45.82M | -43.70M | -58.70M |
| Financing Cash Flow | -27.95M | -2.37M | 72.35M | -46.48M | -43.70M | -97.30M |
| Other Cash Details | ||||||
| End Cash Position | 87.77M | 89.60M | 100.40M | 27.42M | 37.00M | 46.30M |
| Income Tax Paid | 20.15M | 25.73M | 12.09M | 4.65M | — | — |
| Interest Paid | 37.71M | 17.28M | — | — | — | — |
| Free Cash Flow | 24.66M | -1.92M | 7.64M | 47.71M | 66.20M | 113.70M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 862,529 | 12.08M | 3.13% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 769,698 | 10.78M | 2.79% |
| Avantis U.S. Small Cap Value ETF | Nov 30, 2024 | 482,874 | 6.76M | 1.75% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 431,777 | 6.04M | 1.56% |
| Neuberger & Berman Intrinsic Value Fd | Nov 30, 2024 | 428,481 | 6.00M | 1.55% |
| DFA U.S. Small Cap Value Series | Oct 31, 2024 | 328,848 | 4.60M | 1.19% |
| Fidelity Small Cap Index Fund | Oct 31, 2024 | 275,307 | 3.85M | 1.00% |
| iShares Russell 2000 Value ETF | Nov 30, 2024 | 269,301 | 3.77M | 0.98% |
| EQ Advisors Trust-1290 VT Gamco Small Company Value Port | Sep 30, 2024 | 265,000 | 3.71M | 0.96% |
| Schwab Strategic Tr-Schwab Fundamental U.S. Small Company Index ETF | Nov 30, 2024 | 185,053 | 2.59M | 0.67% |
Article
ZimVie Announces Publication of a Study Supporting the Benefits of Its Implant Surface Technologies
Data confirms ZimVie implants meet critical roughness criteria advantageous for long-term peri-implant health Data confirms ZimVie implants meet critical roughness criteria advantageous for long-term peri-implant health
Jan 30, 2025
Article
ZimVie Inc. (ZIMV) Q3 2024 Earnings Call Transcript
ZimVie Inc. (NASDAQ:ZIMV ) Q3 2024 Results Conference Call October 30, 2024 4:30 PM ET Company Participants Marissa Bych - IR, Gilmartin Group LLC Vafa Jamali - President and CEO Richard Heppenstall - CFO Conference Call Participants David Saxon - Needham & Company Matt Miksic - Barclays Marissa Bych Thank you all for joining today's call. Earlier today, ZimVie released financial results for the quarter ended September 30, 2024.
Oct 30, 2024
Article
ZimVie to Report Third Quarter Financial Results on October 30, 2024
PALM BEACH GARDENS, Fla., Oct. 16, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, October 30, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
Oct 16, 2024
